- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Anthem Announces That It Will Acquire Aspire Health
In the latest move by Anthem Inc., the company announced earlier this week that it plans to acquire Aspire Health, the nation’s largest non-hospice advanced care provider.
In the latest move by Anthem Inc., the company announced earlier this week that it plans to acquire Aspire Health, the nation’s largest non-hospice advanced care provider.
“Aspire Health shares our perspective on the increasingly important role of integrated care and has built a unique model that provides palliative care and support for support services for patients and their families,” said Gail K. Boudreaux, president and CEO of Anthem, in a statement.
Aspire was founded in 2013 by former US Senator William Frist, MD, and Brad Smith, who serves as the CEO. The company uses proprietary predictive clinical technology and claims-based patient algorithms to identify patients that have a serious illness who may benefit from added support. Once patients are identified, Aspire establishes a comprehensive integrated care team to address symptom management, coordinated care, and advanced care planning.
“As part of Anthem, we believe we will be able to further scale our model and positively impact the lives of even more consumers and families, making home-based advanced illness care available to patients who need it,” said Smith in a statement.
CMS has previously estimated that the average rate of national health spending will grow 5.5% per year from 2017 to 2026, reaching nearly $5.7 trillion. According to a study published last year in Health Affairs, end-of-life care is among the most expensive healthcare costs, reaching a mean of $80,000 per capita in the last 12 months of life.
In the past, Anthem has attempt to curtail healthcare costs in controversial ways. Last year, it announced that emergency department (ED) visits would no longer be covered by the insurer in cases where it deemed the visit unnecessary. It amended this policy in February 2018, stating that exceptions would be made for patients sent to an ED by a provider, those from out of state who present to the ED on the weekend, and those who end up receiving certain types of medical care such as surgery, intravenous (IV) fluids, or a magnetic resonance imaging (MRI) or computed tomography (CT) scan.
The acquisition is expected to be finalized in the third quarter of 2018, and the financial terms of the acquisition were not disclosed.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars
February 5th 2025Of the 118 biologics losing exclusivity over the next decade, only 10% have biosimilars in development, meaning a vast majority of biologics have no pipeline, which limits savings potential for the health care system.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
